Skip Nav Destination
Issues
1 August 2011
-
Cover Image
Cover Image
Three-dimensional structure of the trastuzumab/pertuzumab/HER2 ternary complex. Yellow, orange, and magenta are trastuzumab, pertuzumab, and HER2, respectively. Trastuzumab and pertuzumab bind to HER2 without competing with each other. For further details, please see Yamashita-Kashima and coworkers on page 5060 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Editor’s Note
CCR Perspectives in Drug Approval
Molecular Pathways
Review
Perspective
Human Cancer Biology
Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma
Takafumi Kubo; Shinichi Toyooka; Kazunori Tsukuda; Masakiyo Sakaguchi; Takuya Fukazawa; Junichi Soh; Hiroaki Asano; Tsuyoshi Ueno; Takayuki Muraoka; Hiromasa Yamamoto; Yasutomo Nasu; Takumi Kishimoto; Harvey I. Pass; Hideki Matsui; Nam-ho Huh; Shinichiro Miyoshi
Cancer Therapy: Preclinical
Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells
Marianne E. Marshall; Trista K. Hinz; Scott A. Kono; Katherine R. Singleton; Brady Bichon; Kathryn E. Ware; Lindsay Marek; Barbara A. Frederick; David Raben; Lynn E. Heasley
Imaging, Diagnosis, Prognosis
High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Johannes H. Schulte; Hagen S. Bachmann; Bent Brockmeyer; Katleen DePreter; André Oberthür; Sandra Ackermann; Yvonne Kahlert; Kristian Pajtler; Jessica Theissen; Frank Westermann; Jo Vandesompele; Frank Speleman; Frank Berthold; Angelika Eggert; Benedikt Brors; Barbara Hero; Alexander Schramm; Matthias Fischer
Cancer Therapy: Clinical
Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
Marc A. Weniger; Edgar G. Rizzatti; Patricia Pérez-Galán; Delong Liu; Qiuyan Wang; Peter J. Munson; Nalini Raghavachari; Therese White; Megan M. Tweito; Kieron Dunleavy; Yihong Ye; Wyndham H. Wilson; Adrian Wiestner
Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study
Steven G. DuBois; Suzanne Shusterman; Ashish M. Ingle; Charlotte H. Ahern; Joel M. Reid; Bing Wu; Sylvain Baruchel; Julia Glade-Bender; Percy Ivy; Holcombe E. Grier; Peter C. Adamson; Susan M. Blaney
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
Shivaani Kummar; Mark Raffeld; Lamin Juwara; Yvonne Horneffer; Agnes Strassberger; Deborah Allen; Seth M. Steinberg; Annamaria Rapisarda; Shawn D. Spencer; William D. Figg; Xiaohong Chen; Ismail Baris Turkbey; Peter Choyke; Anthony J. Murgo; James H. Doroshow; Giovanni Melillo
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi; Alison Stopeck; Hannah Linden; David Solit; Sarat Chandarlapaty; Neal Rosen; Gabriella D'Andrea; Maura Dickler; Mary E. Moynahan; Steven Sugarman; Weining Ma; Sujata Patil; Larry Norton; Alison L. Hannah; Clifford Hudis
Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Danny Rischin; David C. Bibby; Geoff Chong; Gabriel Kremmidiotis; Annabell F. Leske; Clayton A. Matthews; Shirley S. Wong; Mark A. Rosen; Jayesh Desai
Predictive Biomarkers and Personalized Medicine
EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients
Siwen Hu-Lieskovan; Daniel Vallbohmer; Wu Zhang; Dongyun Yang; Alexander Pohl; Melissa J. Labonte; Peter P. Grimminger; Arnulf H. Hölscher; Robert Semrau; Dirk Arnold; Kathrin Dellas; Annelies Debucquoy; Karin Haustermans; Jean-Pascal H. Machiels; Christine Sempoux; Claus Rödel; Matej Bracko; Vaneja Velenik; Heinz-Josef Lenz
p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)
Jonathan F. Lara; Ann D. Thor; Lynn G. Dressler; Gloria Broadwater; Ira J. Bleiweiss; Susan Edgerton; David Cowan; Lori J. Goldstein; Silvana Martino; James N. Ingle; I. Craig Henderson; Larry Norton; Eric P. Winer; Clifford A. Hudis; Matthew J. Ellis; Donald A. Berry; Daniel F. Hayes; for the Cancer and Leukemia Group B
Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials
David Olmos; Richard D. Baird; Timothy A. Yap; Christophe Massard; Lorna Pope; Shahneen K. Sandhu; Gerhardt Attard; Juliet Dukes; Dionysis Papadatos-Pastos; Philippa Grainger; Stan B. Kaye; Johann S. de Bono
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds